Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to seek new opportunities for future growth and enhance its risk resistance [1] Group 1 - The company intends to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd. to acquire a 34% stake [1] - The target company's main business focuses on the research and application of autologous cell technology [1]

格隆汇12月19日丨金达莱(688057.SH)公布,公司基于对干细胞技术的研发与应用等国家战略性新兴行业 发展前景看好，拟逐步优化公司产业结构，为未来发展寻找新的产业机会，以提高公司的抗风险能力， 培育新的利润增长点。公司拟以人民币2.8亿元向济慈医疗增资，其中：515.18万元用于认购济慈医疗 515.18万元的新增注册资本，剩余2.75亿元计入资本公积。本次交易完成后，公司将持有济慈医疗 34.00%的股权。 ...

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a capital increase in Yunnan Jici Medical Technology Co., Ltd. [1] Group 1 - The company intends to invest 280 million yuan of its own funds to acquire a 34% stake in Yunnan Jici Medical Technology Co., Ltd. [1] - Yunnan Jici Medical has unique advantages in the field of cell dedifferentiation and rejuvenation research, having established a technology system that induces skin fibroblasts into specific functional cells without going through the induced pluripotent stem cell (iPSC) stage [1] - The company has developed a series of autologous cell preparations or their derivatives, including first-generation induced mesenchymal stem cells (rFib), second-generation induced mesenchymal stem cells (cFib), induced osteoblasts (iOB), induced chondrocytes (iCH), induced neurons (iNC), induced endothelial cells (iEC), and induced vascular smooth muscle cells (iVSMC) [1] Group 2 - Yunnan Jici Medical has pioneered a new field of autologous cell therapy and tissue engineering for refractory diseases, particularly refractory geriatric diseases, based on its original series of stem cell patent technologies [2] - The company has obtained 20 invention patents in countries including China, the United States, Japan, Canada, Australia, and Malaysia [2]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a capital increase in Yunnan Jici Medical Technology Co., Ltd. [1] Group 1 - The company intends to invest 280 million yuan of its own funds to acquire a 34% stake in Yunnan Jici Medical Technology Co., Ltd. [1] - Yunnan Jici Medical has unique advantages in the field of cell dedifferentiation and rejuvenation research, having established a technology system that induces skin fibroblasts into specific functional cells without going through the induced pluripotent stem cell (iPSC) stage [1] - The company has developed a series of autologous cell preparations or their derivatives, including first-generation induced mesenchymal stem cells (rFib), second-generation induced mesenchymal stem cells (cFib), induced osteoblasts (iOB), induced chondrocytes (iCH), induced neurons (iNC), induced endothelial cells (iEC), and induced vascular smooth muscle cells (iVSMC) [1] Group 2 - Yunnan Jici Medical has pioneered a new field of autologous cell therapy and tissue engineering research for refractory diseases, particularly refractory geriatric diseases, based on its original series of stem cell patent technologies [2] - The company has obtained 20 invention patents in countries including China, the United States, Japan, Canada, Australia, and Malaysia [2]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to seek new opportunities for growth and enhance its risk resistance [1] Group 1: Investment and Strategic Moves - The company intends to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd. (referred to as "Jici Medical") [1] - Upon completion of the transaction, the company will hold a 34% stake in Jici Medical [1] Group 2: Business Focus - The main business of Jici Medical and its subsidiaries is the research and application of autologous cell technology [1]

投资标的名称：云南济慈医疗科技有限公司（以下简称"济慈医疗"、"标 的公司"） 投资金额：江西金达莱环保股份有限公司（以下简称"公司"、"金达 莱"）拟使用自有资金 2.8 亿元向济慈医疗增资，交易完成后公司将持有济慈 医疗 34.00%的股权。 已履行的审议程序：本次对外投资事项已经公司第五届董事会第十一 次会议审议通过，无需提交股东会审议通过。本次对外投资不构成《上市公 司重大资产重组管理办法》规定的重大资产重组，亦不构成关联交易。 相关风险提示：标的公司实际经营过程中可能受宏观经济、行业环境、 市场变化等因素的影响，未来具体经营业绩及投资收益仍存在不确定性。敬 请广大投资者谨慎决策，注意投资风险。 一、对外投资概述 证券代码：688057 证券简称：金达莱 公告编号：2025-034 江西金达莱环保股份有限公司 对外投资公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2 / 11 投资类型 □新设公司 √增资现有公司（□同比例 √非同比例） --增资前标的公司类型：□全资子公司 □控股子公司 □ 参 ...

Core Viewpoint - The company is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to seek new opportunities for growth and enhance its risk resistance [1] Group 1: Investment and Strategic Moves - The company intends to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd. to acquire a 34% stake [1]

12月19日，金达莱盘中上涨2.04%，截至10:41，报11.98元/股，成交440.44万元，换手率0.13%，总市值 33.06亿元。 分红方面，金达莱A股上市后累计派现10.35亿元。近三年，累计派现4.83亿元。 资金流向方面，主力资金净流入53.66万元，大单买入77.02万元，占比17.49%，卖出23.36万元，占比 5.30%。 责任编辑：小浪快报 金达莱今年以来股价涨10.41%，近5个交易日涨1.35%，近20日涨0.42%，近60日跌2.92%。 资料显示，江西金达莱环保股份有限公司位于江西省南昌市新建区长堎外商投资开发区工业大道459 号，成立日期2004年10月29日，上市日期2020年11月11日，公司主营业务涉及以自身污水处理核心工 艺、技术为依托,策略性专注于整体设计、系统集成等环节。主营业务收入构成为：水污染治理项目运 营56.15%，水环境整体解决方案21.29%，水污染治理装备15.40%，其他(补充)7.16%。 金达莱所属申万行业为：环保-环境治理-水务及水治理。所属概念板块包括：PPP概念、小盘、污水处 理、节能环保、融资融券等。 截至9月30日，金达莱股东户数1 ...

证券代码：688057 证券简称：金达莱 公告编号：2025-033 江西金达莱环保股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 非累积投票议案 （一） 股东会召开的时间：2025 年 12 月 2 日 （二） 股东会召开的地点：江西省南昌市新建区长堎外商投资开发区工业大道 459 号 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 103 | | --- | --- | | 普通股股东人数 | 103 | | 2、出席会议的股东所持有的表决权数量 | 138,959,868 | | 普通股股东所持有表决权数量 | 138,959,868 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 50.3477 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...